Expertise in
18
conditions

Dr. Sana D. Karam

Saint Louis, MO
Expertise in
18
conditions
Specialties:Radiation Oncology
Accepting New Patients
Expertise in
18
conditions
OverviewInsuranceLocationsClinical Research

Overview

Sana Karam is a Radiation Oncologist in Saint Louis, Missouri. Dr. Karam is highly rated in 18 conditions, according to our data. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Oral Squamous Cell Carcinoma, and Pancreatectomy. Dr. Karam is currently accepting new patients.

Her clinical research consists of co-authoring 160 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MO
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  UnitedHealthcare
  •  Humana

Locations

4921 Parkview Pl, Dept Radiation Oncology, Ll, Saint Louis, MO 63110
314-747-7236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug, Radiation
Study Drugs: sEphB4-HAS, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Radiation, Drug, Procedure
Study Drug: Durvalumab
Study Phase: Phase 1
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Enrollment Status: Withdrawn
Publish Date: December 06, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nab-paclitaxel, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
Enrollment Status: Completed
Publish Date: May 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

162 Total Publications

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment.
Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment.
Journal: Journal for immunotherapy of cancer
Published: December 18, 2024
Similar Doctors
Expertise in
14
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Expertise in
14
conditions
Dr. Perry W. Grigsby
Radiation Oncology
1 Barnes Jewish Hospital Plz, Dept Radiology, 
Saint Louis, MO 
 (0.2 mi)
314-362-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Perry Grigsby is a Radiation Oncologist in Saint Louis, Missouri. Dr. Grigsby is highly rated in 14 conditions, according to our data. His top areas of expertise are Cervical Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, and Thyroidectomy. Dr. Grigsby is currently accepting new patients.

Expertise in
9
conditions
Dr. Jeff M. Michalski
Radiation Oncology
Expertise in
9
conditions
Dr. Jeff M. Michalski
Radiation Oncology

Washington University

5225 Mid America Plz, 
Saint Louis, MO 
 (11.9 mi)
314-286-1911
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeff Michalski is a Radiation Oncologist in Saint Louis, Missouri. Dr. Michalski is highly rated in 9 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Malignant Peripheral Nerve Sheath Tumor, and Prostatectomy. Dr. Michalski is currently accepting new patients.

Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology
Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology

Washington University

5225 Mid America Plz, 
Saint Louis, MO 
 (11.9 mi)
314-286-1911
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Clifford Robinson is a Radiation Oncologist in Saint Louis, Missouri. Dr. Robinson is highly rated in 26 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Robinson is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile